XML 45 R30.htm IDEA: XBRL DOCUMENT
v3.24.1.1.u2

Summary of Significant Accounting Policies (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2023
Reconciliation of Numerators and Denominators used in Computing Basic and Diluted Net Income Per Share | The following is a reconciliation of the numerators and denominators used in computing basic and diluted net income per share:
|  | Year ended December 31, 2023 |  |  | Year ended December 31, 2022 (As Restated) |
Net income (loss) attributable to Odyssey Marine Exploration, Inc. |  | $ | 5,345,819 |  |  | $ | (22,079,859 | )
Numerator: |  |  |  |  |  |  |  |
Basic net income (loss) |  | $ | 5,345,819 |  |  | $ | (22,079,859 | )
Diluted net income (loss) available to stockholders |  | $ | 5,341,008 |  |  | $ | (22,079,859 | )
Denominator: |  |  |  |  |  |  |  |
Weighted average common shares outstanding – Basic |  |  | 19,943,633 |  |  |  | 17,310,915 |
Dilutive effect of options |  |  | 5,557 |  |  |  | — |
Dilutive effect of warrants |  |  | 169,687 |  |  |  | — |
Dilutive effect of other convertible securities |  |  | — |  |  |  | — |
Weighted average common shares outstanding – Diluted |  |  | 20,118,877 |  |  |  | 17,310,915 |
Net (loss) income per share – basic |  | $ | 0.27 |  |  | $ | (1.28 | )
Net (loss) income per share – diluted |  | $ | 0.27 |  |  | $ | (1.28 | )
Summarize Our Fair Value Hierarchy For Our Financial Assets And Liabilities Measured At Fair Value On A Recurring Basis | The following tables summarize our fair value hierarchy for our financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2023 and 2022:
|  | December 31, 2023 |
|  | Level 1 |  |  | Level 2 |  |  | Level 3 |  |  | Total Balance |
Liabilities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
37N Note embedded derivative |  | $ | — |  |  | $ | — |  |  | $ | 702,291 |  |  | $ | 702,291 |
Put option liability |  |  | — |  |  |  | — |  |  |  | 5,637,162 |  |  |  | 5,637,162 |
Litigation financing |  |  |  |  |  |  |  |  |  |  | 52,115,647 |  |  |  | 52,115,647 |
Warrant liabilities issued with debt (December 2023 Warrants) |  |  |  |  |  |  |  |  |  |  | 2,392,563 |  |  |  | 2,392,563 |
Warrant liabilities issued with equity (2022 Warrants) |  |  |  |  |  |  |  |  |  |  | 13,399,822 |  |  |  | 13,399,822 |
Total of fair valued l iabilities |  | $ | — |  |  | $ | — |  |  | $ | 74,247,485 |  |  | $ | 74,247,485 |
|  | December 31, 2022 (As Restated) |
|  | Level 1 |  |  | Level 2 |  |  | Level 3 |  |  | Total Balance |
Liabilities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant liabilities issued with equity (2022 Warrants) |  | $ | — |  |  | $ | — |  |  | $ | 13,602,467 |  |  | $ | 13,602,467 |
Litigation Financing |  |  | — |  |  |  | — |  |  |  | 45,368,948 |  |  |  | 45,368,948 |
Total of fair valued l iabilities |  | $ | — |  |  | $ | — |  |  | $ | 58,971,415 |  |  | $ | 58,971,415 |
Changes in our Level 3 fair value measurements | Changes in our Level 3 fair value measurements were as follows:
|  | 37N Note embedded derivative |  |  | Put option liability |  |  | Litigation financing |  |  | Warrant liabilities issued with debt (December 2023 warrants) |  |  | Warrant liabilities issued with equity (2022 warrants) |  |  | Total |
Balance as of January 1, 2022 (As Restated) |  |  | — |  |  |  | — |  |  |  | 33,701,188 |  |  |  | — |  |  |  | — |  |  |  | 33,701,188 |
Change in fair value |  |  | — |  |  |  | — |  |  |  | 6,286,172 |  |  |  | — |  |  |  | 3,628,373 |  |  |  | 9,914,545 |
Issuance of new instrument |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 9,974,094 |  |  |  | 9,974,094 |
Issuance of new funding |  |  | — |  |  |  | — |  |  |  | 5,381,588 |  |  |  | — |  |  |  | — |  |  |  | 5,381,588 |
Year ended December 31, 2022 (As Restated) |  |  |  |  |  |  |  |  |  |  | 45,368,948 |  |  |  |  |  |  |  | 13,602,467 |  |  |  | 58,971,415 |
Change in fair value |  |  | 457,690 |  |  |  | 1,121,155 |  |  |  | 6,742,066 |  |  |  | — |  |  |  | (18,045 | ) |  |  | 8,302,866 |
Issuance of new instrument |  |  | 423,696 |  |  |  | 4,516,007 |  |  |  | — |  |  |  | 2,392,563 |  |  |  | — |  |  |  | 7,332,266 |
Issuance of new funding |  |  | — |  |  |  | — |  |  |  | 4,633 |  |  |  | — |  |  |  | — |  |  |  | 4,633 |
Warrants exercised |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (184,600 | ) |  |  | (184,600 | )
Debt conversion to equity |  |  | (179,095 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (179,095 | )
Year ended December 31, 2023 |  |  | 702,291 |  |  |  | 5,637,162 |  |  |  | 52,115,647 |  |  |  | 2,392,563 |  |  |  | 13,399,822 |  |  |  | 74,247,485 |
In the Money Potential Common Shares [Member] |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share | The potential common shares in the following tables represent potential common shares from outstanding options, restricted stock awards, convertible notes and other convertible securities that were excluded from the calculation of diluted EPS during periods due to having an anti-dilutive effect are:
|  | December 31, 2023 |  |  | December 31, 2022 (As Restated) |
Average market price during the period |  | $ | 3.47 |  |  | $ | 4.22 |
Option awards |  |  | 916,111 |  |  |  | 859,999 |
Unvested restricted stock awards |  |  | 10,087 |  |  |  | 213,739 |
Convertible notes |  |  | 462,628 |  |  |  | — |
Put Option Liability |  |  | 4,063,759 |  |  |  | — |
Common Stock Warrant |  |  | 7,948,176 |  |  |  | 8,392,466 |

X
- Definition Tabular disclosure of assets and liabilities by class, including financial instruments measured at fair value that are classified in shareholders' equity, if any, that are measured at fair value on a nonrecurring basis in periods after initial recognition (for example, impaired assets). Disclosures may include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb) -SubTopic 10 -Topic 820 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=omex_InMoneyPotentialCommonSharesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |